Montelukast Accord (Montelukast Sodium)

Montelukast Sodium, the active ingredient in Montelukast Accord, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children.

GNH USA supplies Montelukast Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast Accord, a leukotriene receptor antagonist, is used to manage conditions driven by cysteinyl leukotriene‑mediated inflammation.

- Asthma: improves control of persistent asthma and reduces the frequency of exacerbations. - Allergic rhinitis: relieves nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis. - Exercise‑induced bronchoconstriction: prevents narrowing of the airways that occurs during or after physical activity.

Common Side Effects: - Headache: mild to moderate headache reported in clinical use. - Abdominal pain: occasional stomach discomfort or cramping. - Nausea: transient feeling of queasiness. - Dizziness: light‑headed sensation, usually transient.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema or anaphylaxis requiring immediate medical attention. - Neuropsychiatric events: depression, mood changes, suicidal thoughts or behavior. - Hepatic enzyme elevation: abnormal liver function tests observed rarely. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, consider the following precautions: - Assess asthma control: ensure patient is on appropriate inhaled therapy before adding montelukast. - Monitor neuropsychiatric symptoms: watch for mood changes, depression or suicidal ideation. - Use caution in hepatic impairment: evaluate liver function and adjust therapy if needed. - Avoid in known hypersensitivity: discontinue if allergic reaction to montelukast or excipients occurs. - Store at room temperature (below 25°C): keep in the original pack, protect from moisture.

Montelukast may interact with several medicines; review patient medication lists carefully.

Major Interactions (Avoid): - Phenobarbital: induces metabolism and may lower montelukast plasma levels. - Rifampin: strong enzyme inducer that can reduce montelukast exposure. - Carbamazepine: may decrease montelukast concentrations through hepatic induction.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR; monitor coagulation parameters. - Theophylline: additive bronchodilator effect; observe clinical response. - CYP3A4 inhibitors (e.g., ketoconazole): may increase montelukast levels, requiring observation.